SG11202000054RA - Bispecific anti pd1-anti tim3 antibodies - Google Patents

Bispecific anti pd1-anti tim3 antibodies

Info

Publication number
SG11202000054RA
SG11202000054RA SG11202000054RA SG11202000054RA SG11202000054RA SG 11202000054R A SG11202000054R A SG 11202000054RA SG 11202000054R A SG11202000054R A SG 11202000054RA SG 11202000054R A SG11202000054R A SG 11202000054RA SG 11202000054R A SG11202000054R A SG 11202000054RA
Authority
SG
Singapore
Prior art keywords
bispecific
tim3 antibodies
antibodies
bispecific anti
tim3
Prior art date
Application number
SG11202000054RA
Other languages
English (en)
Inventor
Cecilia Anna Wilhelmina Geuijen
Rinse Klooster
Kruif Cornelis Adriaan De
Paulus Johannes Tacken
Mark Throsby
Ton Logtenberg
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of SG11202000054RA publication Critical patent/SG11202000054RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202000054RA 2017-07-06 2018-07-06 Bispecific anti pd1-anti tim3 antibodies SG11202000054RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17180061 2017-07-06
PCT/NL2018/050450 WO2019009727A1 (en) 2017-07-06 2018-07-06 ANTI-PD1 ANTI-TIM3 BISPECIFIC ANTIBODIES

Publications (1)

Publication Number Publication Date
SG11202000054RA true SG11202000054RA (en) 2020-02-27

Family

ID=59366222

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000054RA SG11202000054RA (en) 2017-07-06 2018-07-06 Bispecific anti pd1-anti tim3 antibodies

Country Status (15)

Country Link
US (2) US11753470B2 (de)
EP (1) EP3649155A1 (de)
JP (1) JP7422655B2 (de)
KR (1) KR20200042467A (de)
CN (1) CN111094348A (de)
AU (1) AU2018297058B2 (de)
BR (1) BR112020000227A2 (de)
CA (1) CA3068932A1 (de)
EA (1) EA202090004A1 (de)
IL (1) IL271832A (de)
MX (1) MX2020000055A (de)
PH (1) PH12020550013A1 (de)
SG (1) SG11202000054RA (de)
TW (1) TW201920657A (de)
WO (1) WO2019009727A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL271833B1 (en) * 2017-07-06 2024-05-01 Merus Nv Antibodies that regulate biological activity expressed by a cell
TW202340257A (zh) * 2018-02-09 2023-10-16 日商小野藥品工業股份有限公司 雙特異性抗體
TW202003569A (zh) * 2018-03-30 2020-01-16 荷蘭商美勒斯公司 多價抗體
US20220213193A1 (en) * 2019-05-06 2022-07-07 Brown University Bispecific antibodies against chi3l1 and pd1 with enhanced t cell-mediated cytotoxic effects on tumor cells
CN114702587A (zh) 2019-05-09 2022-07-05 美勒斯公司 用于使蛋白质多聚化的变体结构域及其分离
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业(上海)股份有限公司 四价双特异性抗体、其制备方法和用途
WO2023089083A1 (en) * 2021-11-19 2023-05-25 Merus N.V. Multispecific binding moieties comprising pd-1 and tgf-brii binding domains

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
SI2161336T1 (sl) 2005-05-09 2013-11-29 Ono Pharmaceutical Co., Ltd. Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki
PL2288715T3 (pl) 2008-04-11 2015-03-31 Merrimack Pharmaceuticals Inc Łączniki będące albuminą surowicy ludzkiej i ich koniugaty
KR102261586B1 (ko) 2008-06-27 2021-06-08 메뤼스 엔.페. 항체 생산 비-인간 포유동물
US9163087B2 (en) * 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
CN114163530A (zh) 2012-04-20 2022-03-11 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
PL2900694T3 (pl) 2012-09-27 2018-12-31 Merus N.V. Dwuswoiste przeciwciała igg jako aktywatory komórek t
SI3110849T1 (sl) 2014-02-28 2021-01-29 Merus N.V. Protitelo, ki veže ERBB-2 in ERBB-3
RU2729371C1 (ru) * 2015-10-02 2020-08-06 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела, специфические к pd1 и tim3
WO2017055399A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Cellular based fret assay for the determination of simultaneous binding
CN115925944A (zh) * 2015-10-23 2023-04-07 美勒斯公司 抑制癌症生长的结合分子
BR112018008891A8 (pt) * 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos

Also Published As

Publication number Publication date
EP3649155A1 (de) 2020-05-13
PH12020550013A1 (en) 2020-10-12
JP7422655B2 (ja) 2024-01-26
JP2020532281A (ja) 2020-11-12
WO2019009727A1 (en) 2019-01-10
CA3068932A1 (en) 2019-01-10
BR112020000227A2 (pt) 2020-09-29
CN111094348A (zh) 2020-05-01
US20200216539A1 (en) 2020-07-09
WO2019009727A8 (en) 2020-01-30
US20230357407A1 (en) 2023-11-09
IL271832A (en) 2020-02-27
EA202090004A1 (ru) 2020-06-18
US11753470B2 (en) 2023-09-12
AU2018297058A1 (en) 2020-01-30
AU2018297058B2 (en) 2021-04-29
TW201920657A (zh) 2019-06-01
KR20200042467A (ko) 2020-04-23
MX2020000055A (es) 2020-08-06

Similar Documents

Publication Publication Date Title
HK1256365A1 (zh) 對pd1和tim3特異性的雙特異性抗體
IL279235A (en) DLL3-CD3 bispecific antibodies
PL3519437T3 (pl) Przeciwciała dwuswoiste przeciwko p95HER2
ZA201801673B (en) Optimized anti¿cd3 bispecific antibodies and uses thereof
ZA201908549B (en) Checkpoint inhibitor bispecific antibodies
IL271832A (en) Bispecific antibodies against PD1 and against TIM3
EP3487888A4 (de) Bispezifischer anti-her2-antikörper
PL3130606T3 (pl) Przeciwciała dwuswoiste aktywujące układ odpornościowy
GB201710838D0 (en) Bispecific antibodies
EP3507307A4 (de) Bispezifische antikörper
IL262776A (en) Human anti-il-1r3 antibodies
ZA202004908B (en) Bispecific antibody
EP3377112A4 (de) Chemisch blockierte bispezifische antikörper
IL269577B (en) Bispecific antibodies anti–pd–l1–anti–tim–3
IL282355A (en) Bispecific antibodies directed to exosomes
EP3693013A4 (de) Bispezifischer antikörper
SG11201610594WA (en) Anti-il4-il 13 bispecific antibodies
IL274676A (en) The bispecific antigen binding composition
EP3728311A4 (de) Bispezifische hiv-1-neutralisierende antikörper
IL272676B (en) Bispecific antibodies against il-4 and il-13
GB201511196D0 (en) Monoclonal antibodies